Search

  • Contáctenos
  • Orden Rápida

Gene Therapy Bioprocessing Solutions

Powering results across gene therapy workflows

Gene therapy manufacturing requires precision across every stage, as even small variations can affect vector yield, purity, and consistency. Thermo Fisher Scientific connects upstream and downstream operations through integrated bioprocessing solutions that unite cell culture, transfection, purification, and analytical tools. This integration helps teams reduce variability, improve reproducibility, and maintain quality from early development through commercial manufacturing.

A workflow-first approach to gene therapy bioprocessing

Optimizing gene therapy depends on how each step connects. Thermo Fisher Scientific integrates media, transfection, harvest, purification, and analytical solutions to help improve productivity and reproducibility across workflows. Aligning upstream and downstream operations helps reduce variability, improve reproducibility, and accelerate the path from development to manufacturing. 

 

Optimize upstream processing

Efficient gene therapy upstream bioprocessing lays the foundation for scalable gene therapy production. Thermo Fisher Scientific supports vector generation from cell line selection and expansion to transfection and harvest with optimized media, feeds, single-use systems, and advanced bioreactor technologies.

Controlled upstream environments help maintain viral vector quality and support consistent performance across scales. Standardized media formulations reduce variability between batches, while single-use bioreactor systems help minimize cross-contamination risk and simplify operations. The Thermo Scientific DynaDrive Single-Use Bioreactor is designed to achieve consistent yields and smooth transitions to manufacturing. Optimized cell culture platforms, combined with process-compatible reagents and automation capabilities, help teams establish reproducible conditions that support vector production. Upstream standardization influences harvest quality, impurity profiles, and downstream processing (DSP) efficiency.

Variability in gene therapy upstream processing (USP) can arise from differences in cell line behavior, media lot-to-lot performance, transfection efficiency, and harvest timing. These factors influence vector titer, empty capsid ratios, and impurity burden, affecting downstream purification and product quality. Workflow-aligned solutions help address variability through standardized cell culture media, reproducible transfection systems, and controlled bioreactor environments. Consistent conditions reduce batch-to-batch differences and support predictable process performance. Monitoring critical process parameters across cell expansion, transfection, and harvest stages helps teams identify variability sources and improve reproducibility from development through manufacturing.

Upstream process design decisions directly affect harvest quality, impurity composition, and downstream purification efficiency. High cell densities can increase host cell protein (HCP) and DNA levels, affecting clarification and purification performance. Transfection methods affect vector quality attributes, while harvest timing influences the empty-to-full capsid ratio. Designing upstream workflows with downstream constraints in mind helps reduce process bottlenecks and improve efficiency. Early consideration of filtration capacity, chromatography requirements, and analytical monitoring needs supports smoother transitions between process stages. Integrated upstream and downstream strategies help teams anticipate challenges, maintain product quality, and accelerate development timelines.

Enhance downstream processing

After vector harvest, downstream operations focus on purification, concentration, and final formulation to achieve consistent product quality. Affinity chromatography resins allow selective vector recovery, while 96-well screening plates simplify resin selection and process optimization.

Connected downstream workflows align clarification, purification, concentration, and formulation steps to support efficient impurity reduction and product quality. Each downstream stage influences the next, making workflow integration important for maintaining vector recovery and process throughput. Clarification strategies affect turbidity levels and residual impurity burdens entering chromatography steps, while affinity-based capture methods influence polishing requirements. Process design choices balance productivity, scalability, and robustness while accounting for upstream process outputs. Filtration technologies, purification tools, and fill-finish solutions that reduce manual handling help teams maintain consistency and accelerate timelines across development and manufacturing stages.

Clarification represents a downstream bioprocessing decision that subsequent purification efficiency and product recovery. The Thermo Scientific Harvest RC Chromatographic Clarifier was evaluated with and without endonuclease treatment for AAV lysate clarification and demonstrated comparable performance in both conditions, achieving >90% AAV recovery, >95% turbidity reduction, and >94% host cell DNA reduction across all product sizes studied. DNA profiles were similar regardless of endonuclease use, and the endonuclease-free process showed a lower predicted cost per batch.1,2 In addition to chromatographic clarification, Thermo Scientific Zeta Plus SP Depth Filters and Thermo Scientific ZB™ Depth Filters can also be applied in AAV clarification workflows to support effective lysate clarification and AAV recovery.

Turbidity, host cell protein, and other process-related impurities represent cross-workflow challenges that affect both upstream harvest quality and downstream purification performance. Effective harvest and clarification strategies influence impurity profiles entering chromatography. Analytical solutions support impurity characterization, process monitoring, and data-driven optimization. Viral titer determination, virus detection systems, and residual plasmid DNA quantification enable teams to monitor impurity clearance across process stages, supporting downstream purification performance and regulatory confidence.

Affinity-based and scalable purification strategies support selective vector recovery and process efficiency across gene therapy workflows. CaptureSelect and POROS resins can achieve high binding capacities and product recovery when integrated with upstream cell culture and downstream formulation steps. Resin screening plates simplify process optimization by enabling parallel evaluation of binding conditions, elution strategies, and impurity clearance profiles. AAV purification workflows integrate upstream production platforms with downstream chromatography solutions designed to maintain vector quality across scales. Workflow-aligned purification approaches help teams balance productivity, purity, and scalability from development through manufacturing.

Solutions designed for AAV and LV production

Gene therapy programs often rely on different viral vector systems, each with specific process needs. Standardize AAV and lentiviral (LV) manufacturing using scalable, compatible technologies that reduce process variation and support consistent quality.

Simplify AAV production

Accelerate AAV scale-up with the Gibco AAV-MAX Helper-Free AAV Production System that combines media, reagents, and protocols designed to support reproducible AAV vector generation in suspension culture. When paired with the DynaDrive Single-Use Bioreactor, POROS CaptureSelect AAVX Affinity Resin, and purification solutions for AAV, this approach supports consistent yield and recovery. The Harvest RC clarifier is designed to simplify primary clarification and reduce the need for nuclease.

Streamline LV production

Efficient gene therapy upstream bioprocessing lays the foundation for scalable gene therapy production. Thermo Fisher Scientific supports vector generation from cell line selection and expansion to transfection and harvest with optimized media, feeds, single-use systems, and advanced bioreactor technologies.

Connecting bioprocessing decisions to production workflows

Gene therapy manufacturing presents distinct challenges, from low viral vector yields to complex multistep processes and evolving regulatory expectations. These factors can slow progress and increase production risk. Simplify complexity in AAV and LV manufacturing with connected, scalable production platforms that reduce variability and advance clinical readiness.

Optimize gene therapy manufacturing

Scaling gene therapy from development to commercial production requires materials that perform consistently under regulated conditions. Thermo Fisher Scientific supplies cGMP-manufactured reagents, single-use consumables, and automation tools designed to maintain process stability as production volumes grow. Our global manufacturing and supply network supports continuity and offers the documentation needed for regulatory review.

Collaboration that accelerates innovation

Refining gene therapy processes often depends on shared experiences. Thermo Fisher Scientific connects developers with technical scientists who specialize in upstream, downstream, and analytical methods. Work conducted in shared innovation centers enables direct collaboration, process evaluation, and knowledge transfer, shortening development cycles and strengthening manufacturing readiness.
 

Frequently asked questions

Aligning upstream and downstream bioprocessing decisions through connected workflows reduces handoff-related variability and improves reproducibility across development stages. Standardized media, single-use systems, and controlled bioreactor platforms support consistent upstream performance, while integrated clarification and purification strategies maintain downstream efficiency. Workflow alignment allows teams to anticipate process interactions, minimize batch-to-batch differences, and establish reproducible conditions from cell culture through final formulation, supporting consistent product quality and manufacturing readiness.

Upstream process design choices influence harvest quality, impurity burden, and downstream efficiency. Cell density, transfection methods, and harvest timing affect vector titer, empty capsid ratios, host cell protein levels, and residual DNA content. These factors determine clarification requirements, chromatography binding capacity, and purification performance. Designing upstream workflows with downstream constraints in mind helps reduce process bottlenecks, maintain product recovery, and improve workflow efficiency.

Chromatographic clarification strategies can simplify workflows while maintaining high product recovery and impurity reduction. The Harvest RC clarifier is designed to simplify primary clarification and reduce the need for nuclease. Effective clarification reduces turbidity and impurity burden entering downstream chromatography, improving binding efficiency, reducing column fouling, and enhancing overall purification performance. Workflow-aligned clarification approaches help teams balance productivity, recovery, and process efficiency.

AAV and lentiviral workflows differ in impurity profiles, process sensitivity, and scalability requirements. AAV production often involves higher empty capsid levels and distinct host cell DNA characteristics. Lentiviral workflows can present different envelope protein considerations and stability challenges. Purification strategies, clarification approaches, and analytical monitoring requirements vary between vector types. Modality-aware bioprocessing solutions help maintain consistency across platforms, allowing teams to adapt upstream and downstream workflows to specific vector characteristics.

Early workflow alignment and scalable bioprocessing solutions help minimize late-stage process changes and support smoother transitions to manufacturing. Selecting standardized media, single-use systems, and cGMP-compatible reagents during development reduces process transfer complexity. Designing upstream processes with downstream clarification and purification requirements in mind helps maintain performance across scales. Early integration of analytical monitoring, regulatory documentation, and supply chain considerations supports manufacturing readiness and accelerates paths to commercial production.

Discover gene therapy resources

Access technical guidance and reference materials that support every stage of gene therapy development and manufacturing. Explore webinars, application notes, and workflow guidance designed to help improve yield, manage complexity, and meet regulatory expectations.

Discover gene therapy resources

Explore other bioprocessing applications

Thermo Fisher Scientific supports a broad range of bioprocessing applications, including monoclonal antibodies (mAbs), cell therapy, gene therapy, and vaccine production. Solutions are designed to maintain consistency and scalability across diverse therapeutic modalities.

For research use or further manufacturing. Not for diagnostic use or direct administration into humans or animals.